Researchers randomly assigned men 1:1 to ADT and docetaxel plus either 600 mg darolutamide twice daily (n = 651) or placebo (n = 655). OS served as the primary endpoint. Secondary endpoints ...

Contrast-enhanced chest, abdomen, and pelvic computed tomography or magnetic resonance imaging and bone scans were conducted at baseline, within 30 days of the last docetaxel cycle, and yearly during ...

Risk stratification according to the number of these risk factors could effectively stratify CRPC patients treated with docetaxel in terms of OS. Conclusions: Age, serum PSA level at the start of ...

have been successfully combined with chemotherapy to prolong OS and PFS in other tumor types. Although monotherapy had limited activity in prostate cancer, we hypothesized that adding pembrolizumab to ...

Results showed a statistically significant improvement in OS with darolutamide plus docetaxel compared with placebo plus docetaxel (hazard ratio [HR], 0.68; 95% CI, 0.57-0.80; P <.0001).

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

In that time, studies of drugs involving Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq and Merck & Co.’s Keytruda have all failed to better the OS achieved by docetaxel. Gilead Sciences ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

Astellas and Pfizer have reported five-year follow-up outcomes from the open-label extension of the randomised Phase III ...

The higher median PFS and OS observed with docetaxel was unexpected," said Dr. Besse. He noted that tusamitamab ravtansine showed better safety data in various important clinical categories.

During the study period, 79 CRPC patients received docetaxel-based chemotherapy at ... died of another cause. The median OS was 22.5 months, and the 1-year OS rate was 78.8 %.